“Codivir Performs Well Against Mutations” | IssueWire

Zyon Ayni - IssueWire

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Code Pharma CEO and Founder, Zyon Ayni, said in a press release on IssueWire: “scientific data on Codivir’s mechanism of action has proven strongly that our drug is effective against all mutations of the coronavirus, including the newly discovered Omicron variant”.

Ayni added: “We have received several emergency approvals and orders for production even before the results of the Phase II study. Hence, we are at a critical stage of exceptionally strong commercial potential and essentially a potential breakthrough in the field of antiviral therapy for Covid-19, Influenza, and other RNA viruses.”